{
    "clinical_study": {
        "@rank": "159785", 
        "arm_group": [
            {
                "arm_group_label": "With MSC", 
                "arm_group_type": "Experimental", 
                "description": "infusion of Mesenchymal stem cells at dose 1 mln cells per kg"
            }, 
            {
                "arm_group_label": "Without MSC", 
                "arm_group_type": "No Intervention", 
                "description": "Without MSC infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant\n      (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis\n      and treatment."
        }, 
        "brief_title": "Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Graft-versus-host Disease", 
            "Relapse"
        ], 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "Infusion of mesenchymal stem cells at day of recovery after BMT for patients with AL, AA and\n      MM for acute GVHD prophylaxis and treatment. Infusion at dose 1 cells mln/kg  at day of\n      white blood cells recovery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  allogenic BMT from related or unrelated donor\n\n        Exclusion Criteria:\n\n          -  Severe infection\n\n          -  Relapse\n\n          -  admission to ICU\n\n          -  refusal of research\n\n          -  patients with graft failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941394", 
            "org_study_id": "NRCH-MSC"
        }, 
        "intervention": {
            "arm_group_label": "With MSC", 
            "description": "Mesenchymal stem cells infusion", 
            "intervention_name": "Mesenchymal stem cells", 
            "intervention_type": "Biological", 
            "other_name": "Mesenchymal stem cells infusion"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GVHD", 
            "Relapse", 
            "Overall Survival"
        ], 
        "lastchanged_date": "September 12, 2013", 
        "location": {
            "contact": {
                "email": "kuzlara@rambler.ru", 
                "last_name": "Elena Parovichnikova, Prof MD PhD", 
                "phone": "+79161487131"
            }, 
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation"
                }, 
                "name": "BMT department"
            }, 
            "investigator": {
                "last_name": "Elena Parovichnikova", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation", 
        "overall_contact": {
            "email": "elenap@blood.ru", 
            "last_name": "Elena Parovichnikova, Prof MD PhD", 
            "phone": "+79161252623"
        }, 
        "overall_contact_backup": {
            "email": "kuzlara@rambler.ru", 
            "last_name": "Larisa Kuzmina, MD PhD", 
            "phone": "+79161487131"
        }, 
        "overall_official": {
            "affiliation": "National Research Center for Hematology", 
            "last_name": "Elena Parovichnikova, Prof MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "GVHD", 
            "safety_issue": "Yes", 
            "time_frame": "Every 30 day for 1 year after BMT"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941394"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Research Center for Hematology, Russia", 
            "investigator_full_name": "Elena N.Parovichnikova", 
            "investigator_title": "Head of BMT department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "22242033", 
            "citation": "Kuzmina LA, Petinati NA, Parovichnikova EN, Lubimova LS, Gribanova EO, Gaponova TV, Shipounova IN, Zhironkina OA, Bigildeev AE, Svinareva DA, Drize NJ, Savchenko VG. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int. 2012;2012:968213. doi: 10.1155/2012/968213. Epub 2011 Dec 25."
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "Every 30 day for 1 year after BMT"
            }, 
            {
                "measure": "Relapse-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "Every 30 day for 1 year after BMT"
            }, 
            {
                "measure": "Infection rate", 
                "safety_issue": "Yes", 
                "time_frame": "Every 30 day for 1 year after BMT"
            }
        ], 
        "source": "National Research Center for Hematology, Russia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Research Center for Hematology, Russia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}